Zheng et al. identified a new DGKθ activator by screening an in‐house natural product library for molecules capable of inhibiting the sn‐1,2‐DAG‐PKCε signaling axis, which is involved in metabolic diseases related to obesity and insulin resistance. Here, DGKB is linked to metabolic disease.